Who we are

We are a medical diagnostics company advancing groundbreaking technologies to revolutionize cancer prevention. Our innovative, non-invasive technologies are transforming the detection of esophageal precancer, empowering clinicians and enabling timely interventions.


Enabling early detection, earlier

Our mission is to empower clinicians to save lives by enabling early detection and treatment of esophageal precancer, preventing its progression to lethal cancer.

Culture of trailblazers

Meet the leadership team

Our diverse and seasoned team of scientists, clinicians, engineers, communicators, and industry experts operate with a shared commitment to improving the lives of patients.

View  Team


May 2018

Lucid Diagnostics and Case Western Reserve University Finalize Definitive Licensing Agreement for Groundbreaking EsoCheck® and EsoGuard® Technology

June 2019

FDA 510(K) Clearance for EsoCheck Cell Collection Device

December 2019

Commercial Launch of EsoGuard Esophageal DNA as an Laboratory Developed Test (LDT)

February 2020

U.S. FDA Grants Breakthrough Device Designation for EsoGuard Esophageal DNA Test

April 2020

EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award

January 2021

Final and effective Medicare payment determination for the EsoGuard DNA test

October 2021

Lucid Diagnostics Nasdaq Initial Public Offering (LUCD)

March 2022

Opens LucidDx Labs Inc., a CLIA-certified, CAP-accredited clinical laboratory

April 2022

American College of Gastroenterology clinical guideline supports esophageal precancer screening using Lucid Diagnostics technologies

August 2022

American Gastroenterological Association Clinical Practice Update supports esophageal precancer screening using Lucid Diagnostics technologies

February 2023

First #CheckYourFoodTube Precancer Testing Event in partnership with San Antonio Fire Department

June 2023

Launch of the First EsoGuard Mobile Test Unit

Lucid's Lab

The innovative Lucid Diagnostics lab is CLIA certified, CAP Accredited, and licensed by the New York State Department of Health.

Contact Us

Get in touch with our team


Join our team

At Lucid Diagnostics, we believe early detection will make esophageal cancer a disease of the past. We're using targeted next generation sequencing to fundamentally change the way esophageal precancer is detected. Join a diverse and inclusive team where collaboration and accountability are the foundation of our success.

View positions